Publications by authors named "H De la Fuente"
Detecting the association of genetic variants to the response of biological therapy represents an important advance in developing a personalized therapy. The aim of this work was to study the association of polymorphisms with an optimal response to tildrakizumab in patients with psoriasis in a real-life clinical practice. Ninety patients with plaque psoriasis recruited from-Spanish hospitals receiving tildrakizumab for at least 24 weeks were genotyped for 180 polymorphisms.
View Article and Find Full Text PDFArticle Synopsis
- - Long-COVID (LC) is defined by lingering symptoms for over 3 months post-COVID-19 infection, potentially caused by immune system dysregulation and chronic inflammation.
- - The study identifies specific CD4 T cell subpopulations in COVID-19 recovery and reveals that certain CCR6-expressing T cells are reduced in LC patients, while others increase.
- - LC patients demonstrate lower levels of IFN-γ-secreting CD8 T cells when exposed to the SARS-CoV-2 Spike protein, highlighting the importance of CCR6 in understanding LC's underlying mechanisms.
Beneficial effect of temporary methotrexate interruption on B and T cell responses upon SARS-CoV-2 vaccination in patients with rheumatoid arthritis or psoriatic arthritis.
NPJ Vaccines
January 2024
Article Synopsis
- A study evaluated the immune response of rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients to COVID-19 vaccines after stopping methotrexate (MTX) treatment for 1 or 2 weeks compared to those who continued MTX.
- Patients who paused MTX showed higher levels of antibodies and a stronger T-cell response, particularly in the group that withdrew for 2 weeks.
- Importantly, stopping MTX did not lead to increased flare-ups of RA or PsA, suggesting that a temporary withdrawal could enhance vaccine effectiveness without risking disease stability.
Background: Prediction of the response to a biological treatment in psoriasis patients would allow efficient treatment allocation.
Objective: To identify polymorphisms associated with secukinumab response in psoriasis patients in a daily practice setting.
Methods: We studied 180 SNPs in patients with moderate-to-severe plaque psoriasis recruited from 15 Spanish hospitals.
Article Synopsis
- Primary Sjögren's syndrome (pSS) is an autoimmune disorder influenced by type I and II interferons, with an inadequate focus on the role of innate immune cells like NK and dendritic cells.
- Researchers found a specific NK cell subset in pSS patients that is more effective at killing cells and detected higher levels of a certain type of dendritic cell (cDC2) involved in inflammation.
- The study suggests that the interaction between these NK cells and cDC2s, along with specific signaling pathways, plays a key role in pSS development, highlighting potential new targets for therapy.